NuGen Medical Devices Inc.
NGMDF
$0.02
$0.00-1.89%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -84.69% | -75.03% | -25.07% | 205.89% | 197.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -84.69% | -75.03% | -25.07% | 205.89% | 197.06% |
| Cost of Revenue | -83.87% | -74.85% | -36.31% | 190.01% | 181.61% |
| Gross Profit | -85.45% | -75.22% | -12.39% | 222.50% | 213.50% |
| SG&A Expenses | -7.14% | -25.39% | -41.27% | -21.96% | -41.07% |
| Depreciation & Amortization | -15.87% | -21.18% | -27.53% | -7.08% | -10.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.25% | -28.83% | -39.79% | -15.03% | -33.65% |
| Operating Income | -1.35% | 19.86% | 41.51% | 26.91% | 44.04% |
| Income Before Tax | -463.81% | -46.46% | 73.99% | 57.59% | 79.11% |
| Income Tax Expenses | 342.31% | 629.41% | -101.50% | -43.75% | -68.67% |
| Earnings from Continuing Operations | -463.17% | -47.24% | 74.11% | 57.54% | 79.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -463.17% | -47.24% | 74.11% | 57.54% | 79.07% |
| EBIT | -1.35% | 19.86% | 41.51% | 26.91% | 44.04% |
| EBITDA | -0.24% | 23.41% | 47.12% | 30.67% | 47.99% |
| EPS Basic | -420.90% | -38.12% | 76.45% | 61.75% | 81.49% |
| Normalized Basic EPS | -169.74% | 2.72% | 58.47% | 44.20% | 66.52% |
| EPS Diluted | -420.90% | -38.12% | 76.45% | 61.75% | 81.49% |
| Normalized Diluted EPS | -169.74% | 2.72% | 58.47% | 44.20% | 66.52% |
| Average Basic Shares Outstanding | 3.30% | 5.82% | 7.49% | 10.65% | 16.77% |
| Average Diluted Shares Outstanding | 3.30% | 5.82% | 7.49% | 10.65% | 16.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |